Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2276
Post Holdings
POST
$3.3B
| $4.54M | ﹤0.01% |
45,791
-118,551
| -72% | -$12.3M |
2013 Q2
50 quarters
|
|
2277
Adaptive Biotechnologies
ADPT
$4.62B
| $4.53M | ﹤0.01% |
279,122
-8,152
| -3% | -$133K |
2019 Q2
26 quarters
|
|
2278
CALL
Intuitive Surgical
ISRG
$143B
| $4.53M | ﹤0.01% |
8,000
-12,400
| -61% | -$6.6M |
2025 Q1
3 quarters
|
|
2279
Fulgent Genetics
FLGT
$595M
| $4.53M | ﹤0.01% |
172,286
-6,581
| -4% | -$171K |
2020 Q2
22 quarters
|
|
2280
CVB Financial
CVBF
$3.92B
| $4.52M | ﹤0.01% |
242,870
+47,283
| +24% | +$904K |
2016 Q2
38 quarters
|
|
2281
Rezolute
RZLT
$403M
| $4.51M | ﹤0.01% |
1,911,066
+1,601,370
| +517% | +$12.6M |
2024 Q4
4 quarters
|
|
2282
CALL
Rocket Lab Corp
RKLB
$46.1B
| $4.5M | ﹤0.01% |
64,500
| – | – |
2024 Q4
4 quarters
|
|
|
NSCI
2283
Nuveen Securitized Income ETF
NSCI
$227M
| $4.5M | ﹤0.01% |
+178,760
| New | +$4.5M |
2025 Q4
0 quarters
|
|
|
JHG
2284
DELISTED
Janus Henderson
JHG
| $4.49M | ﹤0.01% |
94,476
-159,541
| -63% | -$7.06M |
2017 Q2
34 quarters
|
|
2285
Veeco
VECO
$3.46B
| $4.49M | ﹤0.01% |
156,953
+13,502
| +9% | +$400K |
2013 Q2
50 quarters
|
|
2286
ProShares S&P 500 ex-Health Care ETF
SPXV
$41.4M
| $4.47M | ﹤0.01% |
60,000
| – | – |
2023 Q2
10 quarters
|
|
2287
Helmerich & Payne
HP
$4.03B
| $4.47M | ﹤0.01% |
155,861
-5,628
| -3% | -$149K |
2013 Q2
50 quarters
|
|
|
NXRT
2288
NexPoint Residential Trust
NXRT
$471M
| $4.47M | ﹤0.01% |
148,501
+8,615
| +6% | +$264K |
2015 Q2
42 quarters
|
|
2289
Materion
MTRN
$6.55B
| $4.47M | ﹤0.01% |
35,936
+1,190
| +3% | +$147K |
2013 Q2
50 quarters
|
|
2290
Ardelyx
ARDX
$875M
| $4.45M | ﹤0.01% |
763,364
+34,722
| +5% | +$193K |
2023 Q1
11 quarters
|
|
2291
Team
TISI
$132M
| $4.43M | ﹤0.01% |
313,766
+14,238
| +5% | +$213K |
2022 Q3
13 quarters
|
|
2292
PUT
Cipher Digital
CIFR
$6.26B
| $4.43M | ﹤0.01% |
+300,000
| New | +$5.3M |
2025 Q4
0 quarters
|
|
2293
Four Corners Property Trust
FCPT
$2.35B
| $4.42M | ﹤0.01% |
191,645
-1,209
| -0.6% | -$28.8K |
2015 Q4
40 quarters
|
|
2294
United Natural Foods
UNFI
$2.73B
| $4.42M | ﹤0.01% |
131,223
+13,400
| +11% | +$498K |
2013 Q2
50 quarters
|
|
|
CGAU
2295
Centerra Gold
CGAU
$4.21B
| $4.42M | ﹤0.01% |
307,453
-87,049
| -22% | -$1.09M |
2022 Q3
13 quarters
|
|
2296
GeneDx Holdings
WGS
$2.23B
| $4.41M | ﹤0.01% |
33,936
-12,044
| -26% | -$1.65M |
2024 Q2
6 quarters
|
|
|
GTM
2297
ZoomInfo Technologies
GTM
$1.09B
| $4.41M | ﹤0.01% |
433,436
-840,668
| -66% | -$8.66M |
2022 Q1
15 quarters
|
|
2298
Alphatec Holdings
ATEC
$1.61B
| $4.4M | ﹤0.01% |
209,266
+26,826
| +15% | +$497K |
2019 Q2
26 quarters
|
|
2299
Omnicell
OMCL
$1.55B
| $4.39M | ﹤0.01% |
96,863
-3,083
| -3% | -$113K |
2013 Q2
50 quarters
|
|
2300
Mobileye
MBLY
$6.44B
| $4.38M | ﹤0.01% |
419,540
+88,325
| +27% | +$1.1M |
2023 Q3
9 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.